Health
Sequana Medical Announces U.S. Commercial alfapump® Implantations at University of Pennsylvania
Ghent, Belgium, Dec. 11, 2025 (GLOBE NEWSWIRE) -- First implantation of two alfapump patients on the same dayContinuing strategy of working with Key Opinion Leaders at top tier centersStrong pipeline of additional implanting centers supports commercial momentumOngoing progress in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosis Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the trea
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I6pT.8uzi87Vh1qGIu6GAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, Dec. 11, 2025 (GLOBE NEWSWIRE) --","length":49,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"First implantation of two alfapump patients on the same day","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Continuing strategy of working with Key Opinion Leaders at top tier centers","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong pipeline of additional implanting centers supports commercial momentum","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Ongoing progress in bringing breakthrough treatment option to US patients with recurrent and refractory ascites due to liver cirrhosis","length":134,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":345,"olType":false},{"type":"text","content":"Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced the successful completion of the first commercial implantations of the alfapump® System at the University of Pennsylvania, with two patients implanted on the same day. The alfapump System is the first active implantable medical device approved in the U.S. for the treatment of recurrent or refractory ascites due to liver cirrhosis that automatically and continuously removes ascites fluid from the abdomen into the bladder.","length":627,"tagName":"p"},{"type":"text","content":"These successful implantations at University of Pennsylvania follow the successful procedure at Mount Sinai Hospital in New York and are further demonstration of the Company’s strategy of working with Key Opinion Leaders at top tier centers to establish alfapump as the new standard of care. Sequana Medical continues to make strong progress in the roll-out of t...